C225 and PDT combination therapy for ovarian cancer: The play's the thing

Journal of the National Cancer Institute

Volumn 97, Issue 20, 2005, Pages 1488-1489

  Cengel, Keith A ^a   Hahn, Stephen M ^a   Glatstein, Eli ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOTOFRIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BENZOPORPHYRIN D; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; EDITORIAL; ENZYME RELEASE; FEMALE; FOLLOW UP; HUMAN; MONOTHERAPY; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT OUTCOME; ANIMAL; CARCINOMA; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LOW LEVEL LASER THERAPY; METASTASIS; METHODOLOGY; MOUSE; NOTE; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHOTOCHEMOTHERAPY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; DRUG SYNERGISM; FEMALE; HEMATOPORPHYRIN PHOTORADIATION; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; LASER THERAPY, LOW-LEVEL; MICE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 27144504234     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji360     Document Type: Editorial

References (13)

1. del Carmen MG, Rizvi I, Chang Y, Moor ACE, Oliva E, Sherwood M, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005;97:1516-24.
2. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
3. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
4. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005;92: 1737-45.
5. Blank SV, Chang R, Muggia F. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology (Williston Park) 2005;19:553-9; discussion 560-2, 567.
6. Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D, et al. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 2004;22:2192-201.
7. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 2001;8:65-71.
8. Wilson JJ, Jones H, Burock M, Smith D, Fraker DL, Metz J, et al. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol 2004;24:711-7.
9. Fanuel-Barret D, Patrice T, Foultier MT, Vonarx-Coinsmann V, Robillard N, Lajat Y. Influence of epidermal growth factor on photodynamic therapy of glioblastoma cells in vitro. Res Exp Med (Berl) 1997;197:219-33.
10. Tong Z, Singh G, Rainbow AJ. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from Photofrin-mediated photodynamic therapy. Cancer Res 2002;62:5528-35.
11. Ahmad N, Kalka K, Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy Oncogene 2001;20:2314-7.
12. Wong TW, Tracy E, Oseroff AR, Baumann H. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003;63:3812-8.
13. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sabin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.